We report a patient who developed a meticillin-resistant Staphylococcus aureus (MRSA) central venous catheter infection complicated by infective endocarditis. The patient was initially treated with glycopeptides, which led to the development of heterogeneous glycopeptide resistance, the detection of which required the use of a macro Etest screening test. Subsequently, the causative strain, confirmed by PFGE as a UK epidemic MRSA-15, was treated with daptomycin, and again resistance developed in vivo. The development in vivo of resistance to both these agents suggests that the resistance mechanisms may be associated. We suggest that the clinician managing MRSA infection should anticipate daptomycin resistance when reduced glycopeptide susceptibility is detected.
Case report
A 41-year-old male with worsening renal function of unknown aetiology was admitted to the Royal Liverpool University Hospital. A Tesio catheter (double lumen and tunnelled) was inserted in the internal jugular vein for dialysis. A week later, pus was noted at the exit site of the Tesio from which meticillin-resistant Staphylococcus aureus (MRSA) was isolated and for which intravenous (i.v.) vancomycin was given. The infection appeared to resolve and the catheter remained in situ.
The following month, on 26 March 2005, he was readmitted with rigors, an inflamed exit site and temporary visual loss. MRSA was isolated from blood cultures taken through the catheter. This and subsequent isolates were speciated using standard methods. Antimicrobial susceptibilities were completed using the British Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method (BSAC, 2007 (Voss et al., 2007) . This was obtained at the time of testing though in our retrospective assessment a macro Etest MIC of only 6 mg l 21 was found (Table 2) . [Changes in MICs for hGISA isolates have been reported elsewhere (Boyle-Vavra et al., 2000) .] The isolate was confirmed as hGISA by population analysis profile-area underneath the curve analysis (PAP-AUC). PAP-AUC is the 'gold standard' for detecting hGISA. Here the AUC of the test S. aureus is divided by the corresponding AUC for Mu 3 (Wootten et al., 2001) , an hGISA type strain. A ratio of ¢0.9 is consistent with hGISA. Our isolate had a PAP-AUC ratio of 0.95. Following this, oral linezolid at 600 mg b.d. was commenced. The source of infection was not identified despite investigation including a TOE.
On 26 January 2006, day 45 of linezolid treatment, blood cultures grew MRSA sensitive to linezolid. Linezolid treatment was continued with the addition of gentamicin for 3 weeks (this isolate was fusidic acid-resistant; Table 2 ). A TOE performed in February 2006 showed two vegetations on the mitral valve. Antimicrobial therapy was changed to daptomycin 6 mg kg 21 every 48 h, oral rifampicin 600 mg b.d. and 80 mg i.v. gentamicin postdialysis for the first 2 weeks. In April, a repeat MRSA bacteraemia occurred. This isolate was still sensitive to daptomycin, leading to the addition of gentamicin. , with our experience of using high-dose teicoplanin, it was decided to administer teicoplanin with the aim of obtaining levels sufficient to negate the isolate's increased MICs. Hence, i.v. teicoplanin at 1.6 g daily for 1 week, then approximately every 48 h, Murchan et al., 2003) . This demonstrated that the isolates were one clonal type by PFGE (Fig. 1) . Comparison with NCTC strain 8325 and the molecular mass marker (data not shown) identified the strain as a UK epidemic MRSA-15, the most prevalent strain of MRSA in our institution.
The patient remained asymptomatic for 6 months, when in December 2006 he presented again with rigors. Blood cultures were taken from which MRSA was isolated. A TOE showed no evidence of endocarditis but a radiolabelled white cell scan suggested osteomyelitis of the humerus, not at the site of the fistula. i.v. tigecycline (MIC 0.094 mg l 21 ) was given for a period of 2 months and clindamycin for 1 month, the isolate testing sensitive to clindamycin. The patient responded both clinically and radiologically and has remained infection-free since. Fig. 2 gives an overview of this case history.
Discussion
The MRSA infection treated with glycopeptides in this report developed, in vivo, hGISA prior to developing GISA in response to this glycopeptide therapy. hGISA populations are those where approximately one subclone in every 1610 6 is able to grow in the presence of a higher concentration of a glycopeptide. The concern is that treatment will fail to eradicate the resistant subpopulation, which will fill the niche left by the killed susceptible population, leading to the clinical failure of glycopeptide therapy. The outcomes in hGISA infections were recently reviewed by Falagas et al. (2008) . The evidence was inconclusive with a limited number of retrospective studies showing both adverse and no adverse outcomes. There is therefore still a need for prospective evaluation of outcomes in S. aureus-infected glycopeptide-treated patients.
In view of the hGISA/GISA resistance, this patient was treated with daptomycin, which led to the development of daptomycin resistance in vivo. Sharma et al. (2008) also found that in patients with S. aureus infection, mainly endocarditis, treated with daptomycin, development of daptomycin resistance was not an uncommon finding.
The mechanisms of hGISA, GISA and daptomycin resistance are still being investigated and may vary between strains. A proposed mechanism involves the upregulation of peptidoglycan synthesis leading to hGISA. In the presence of this upregulation, a further mutation allows significant cell wall thickening, causing a GISA phenotype (Neoh et al., 2008) . The GISA phenotype, as we found, has been shown before to be associated with daptomycin resistance (Vikram et al., 2005; Hayden et al., 2005) . It is suggested that daptomycin, the bactericidal effects of which are due to binding to the bacterial cell membrane, which causes an efflux of potassium ions from the cell and subsequent cell death (Silverman et al., 2003) , is prevented from exerting its anti-staphylococcal action by the thickened cell wall (Jones et al., 2008) . The thickened cell wall, with abundant daptomycin binding sites, sequesters and blocks daptomycin, preventing its action (Cui et al., 2003) . In vitro studies have shown an association of reduced susceptibility to daptomycin with reduced susceptibility to glycopeptides (Sakoulas et al., 2006; Patel et al., 2006) . Thus our case highlights that in patients with MRSA infection who demonstrate hGISA or GISA, which may require use of the macro Etest MIC for detection, clinicians 
